Value of Percutaneous Transhepatic Gallbladder Drainage for Advanced Acute Cholecystitis as a Bridging Procedure

By -

 

Executive Summary

This briefing document analyzes the findings of a single-center retrospective study (2018–2023) evaluating the efficacy and safety of Percutaneous Transhepatic Gallbladder Drainage (PTGBD) for patients with advanced acute cholecystitis (AC) who are unfit for early laparoscopic cholecystectomy (LC).

The analysis confirms that PTGBD is a highly effective bridging strategy for infection control, achieving clinical and biochemical resolution in 92.4% of high-risk patients. However, the procedure is associated with a significant complication rate of 36.2%, primarily involving drain-related issues and recurrent cholecystitis. While 80.9% of patients successfully transitioned to delayed laparoscopic cholecystectomy, these surgeries were characterized by long operative times and a 10.6% conversion rate to open surgery. The study concludes that while PTGBD is a vital tool for stabilizing critically ill or elderly patients, it requires careful patient selection and a standardized approach to manage its inherent procedural risks.

1. Study Overview and Patient Demographics

The study was conducted at the Cantonal Hospital of Fribourg, Switzerland, involving 105 patients treated over a six-year period. The cohort represented a high-risk surgical population.

1.1 Patient Profile

  • Mean Age: 69.9 years.

  • Gender: 63.8% Male.

  • Surgical Risk: 60% of patients were classified as ASA score III or IV, indicating severe systemic disease.

  • Comorbidities:

    • Cardiovascular Disease: 40.95%

    • Obesity (BMI > 30): 34.29%

    • Diabetes: 28.57%

    • Anticoagulant/Double Antiplatelet Therapy: 28.57%

    • Chronic Kidney Disease: 14.29%

1.2 Indications for PTGBD vs. Early Surgery

Standard guidelines recommend early LC within 72 hours of symptom onset. In this study, PTGBD was utilized when early surgery was deemed unfeasible due to:

  • Symptom Duration: Symptoms lasting >3 days (44.76% of cases).

  • Severe Inflammation: C-reactive protein > 300 mg/dL or sepsis (21.90%).

  • Antithrombotic Therapy: High risk of bleeding (16.19%).

  • Worsening Status: 47.62% of patients received PTGBD specifically because inflammatory markers worsened despite antibiotic therapy.

2. Procedure and Primary Outcome: Infection Control

2.1 Technical Execution

PTGBD was performed with a 99.1% technical success rate, typically using ultrasound guidance (83.8%) and an 8.5 French pigtail catheter. The median delay from admission to drainage was one day. Notably, 97.1% of procedures were performed under local anesthesia, minimizing the need for general anesthesia in fragile patients.

2.2 Efficacy in Infection Control

The primary outcome of infection control was achieved in 92.38% (97/105) of patients.

  • Predictors of Failure: Advanced age was identified as the only independent predictor of PTGBD treatment failure in multivariate analysis (OR 0.84, p = 0.015).

  • Mortality: The 30-day mortality rate was 4.8% (5 deaths), all resulting from failure to control infection and subsequent septic shock.

3. Complications and Hospital Outcomes

While effective for stabilization, PTGBD carries a notable burden of secondary complications.

3.1 Procedure-Related Complications

According to the Clavien–Dindo classification, 50% of these complications were Grade 3 (requiring surgical, endoscopic, or radiological intervention), and 18% were Grade 4 (life-threatening).

3.2 Readmission and Stay

  • Mean Hospital Stay: 10.25 days.

  • ICU Admission: 23.81% of patients required intensive care.

  • 30-Day Readmission: 15.24%, primarily due to recurrent cholecystitis (37.5%) or drain issues (25%).

4. Surgical Outcomes of Delayed Cholecystectomy

The study highlights that PTGBD effectively "bridges" patients to surgery, with 80.9% (85/105) eventually undergoing delayed laparoscopic cholecystectomy.

4.1 Surgical Statistics

  • Timing: Surgery occurred an average of 65.7 days after PTGBD (approx. 10 weeks).

  • Operative Time: Relatively long, averaging 141 minutes (range: 50–304 minutes).

  • Conversion Rate: 10.59% of cases required conversion to open surgery, primarily due to dense adhesions (44.4%) or severe inflammation (33.3%).

4.2 Postoperative Complications

16.47% of surgical patients experienced postoperative complications, including:

  • Surgical site and scar infections.

  • Biliary leakage.

  • Cardiogenic shock.

  • One death related to postoperative pneumonia in an elderly patient.

Statistical analysis revealed that the interval between drainage and surgery (e.g., before vs. after 6 weeks) did not significantly impact conversion rates or the occurrence of complications.

5. Conservative Management Outcomes

Thirteen patients (13.4%) were managed conservatively without definitive surgery, mostly due to persistent medical ineligibility or death from unrelated causes.

  • Success Rate: Drain removal was successful in 90% of survivors.

  • Recurrence: 30% experienced recurrent AC, and 40% required reinsertion of a drain.

  • Long-term Efficacy: The findings suggest PTGBD is often insufficient as a definitive therapy; patients managed without surgery faced high rates of recurrence and repeat interventions.

6. Conclusions and Clinical Implications

The research underscores PTGBD as a valuable, life-saving therapeutic option for high-risk patients. Its primary value lies in its ability to rapidly decompress the gallbladder and control infection with minimal anesthetic risk.

Key Insights for Clinical Practice:

  • Bridging vs. Definitive Treatment: PTGBD should be viewed primarily as a bridging procedure. Conservative management alone is associated with high recurrence rates (30%).

  • Procedural Risks: The high rate of drain dislodgement (22%) suggests a need for standardized protocols regarding drain care and monitoring.

  • Surgical Difficulty: Delayed LC after PTGBD remains technically demanding, characterized by long operative times and a higher risk of conversion than standard early LC, though timing (the "6-week rule") may be less critical than previously thought.

  • Risk Factors: Advanced age is a critical factor in determining the potential for PTGBD failure, requiring more intensive monitoring of elderly populations.